For adult patients with CML failing on one 2G TKI, ICLUSIG®
combines experience and data to improve their futures1–3*
CML
ICLUSIG is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic
myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or
nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the
T315l mutation
Also available
for your
patients with Ph+ ALL
Ph+ ALL
ICLUSIG is indicated in adult patients with Philadelphia
chromosome positive acute lymphoblastic leukaemia
(Ph+ ALL) who are resistant to dasatinib; who are
intolerant to dasatinib and for whom subsequent
treatment with imatinib is not clinically appropriate;
or who have the T315l mutation
You are now leaving iclusig.eu. This link will take you to a site that is not owned or maintained
by Incyte, and Incyte is not responsible for the information contained on third-party sites.